中國奧園(03883.HK)9億元出售羅便臣道多項物業 擬作償還貸款及營運資金
中國奧園(03883.HK)公佈,以現金9億元,向獨立第三方伍登輝出售集團位於香港羅便臣道多項物業,以及集團持有這些物業的附屬公司結欠集團的所有款項。
被出售的物業位於羅便臣道63號、65號、65A號及67號,持有這些物業的附屬公司於2019年3月向土地審裁處申請強拍,要求頒令銷售香港羅便臣道63、65、65A及67號燕貽大廈餘下單位。訴訟程序已排期於明年2月審理。
集團預期,出售事項的估計虧損約1.77億元,即出售事項所得款項淨額與出售集團的賬面值之間的差額,出售事項的所得款項淨額擬用於償還貸款融資及用作一般營運資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.